You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Profile for Hong Kong Patent: 1176004


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Hong Kong Patent: 1176004

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,851,502 Feb 19, 2029 Astrazeneca Ab FARXIGA dapagliflozin
8,221,786 Sep 21, 2028 Astrazeneca Ab FARXIGA dapagliflozin
8,221,786 Sep 21, 2028 Astrazeneca Ab QTERN dapagliflozin; saxagliptin hydrochloride
8,361,972 Sep 21, 2028 Astrazeneca Ab BYDUREON exenatide synthetic
8,361,972 Sep 21, 2028 Astrazeneca Ab BYDUREON PEN exenatide synthetic
8,361,972 Sep 21, 2028 Astrazeneca Ab BYDUREON BCISE exenatide synthetic
8,361,972 Sep 21, 2028 Astrazeneca Ab FARXIGA dapagliflozin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of the Scope, Claims, and Patent Landscape for Hong Kong Patent HK1176004

Last updated: July 27, 2025

Introduction

Hong Kong patent HK1176004 pertains to a novel pharmaceutical invention aimed at addressing specific medical needs. As an influential jurisdiction for intellectual property, Hong Kong's patent landscape offers crucial insights into innovation trends, competitive positioning, and legal safeguards within the pharmaceutical sector. This analysis aims to dissect the scope and claims of HK1176004, contextualize its strategic significance, and evaluate its landscape within the broader patent ecosystem.

Overview of Patent HK1176004

Hong Kong patent HK1176004 was granted on [Insert date], with a focus on [describe general invention, e.g., a new drug compound, formulation, or delivery method]. The patent claims to provide [state the intended benefit—e.g., improved efficacy, reduced side effects, novel delivery mechanism]. Its priority date traces back to [Insert priority date], indicating the filing period during which the invention was conceived and registered.

Scope of the Patent

The scope of HK1176004 centers on [describe the innovative subject matter, e.g., a chemical entity, a method of manufacturing, or a therapeutic use]. The patent aims to secure exclusive rights over:

  • The specific chemical structure or composition of the drug.
  • The method of synthesis or formulation.
  • The therapeutic application or treatment method.

The scope is meticulously defined via detailed claims that specify the boundaries of the invention, seeking to deter unauthorized use or replication by competitors.

Key Elements Covering Scope:

  • Chemical Composition: The patent delineates the molecular structure of the active pharmaceutical ingredient (API), potentially including derivatives, salts, or polymorphs.
  • Method of Manufacture: Processes for synthesizing the API, emphasizing uniqueness or efficiency.
  • Therapeutic Use: Particular medical indications or patient populations for whom the drug demonstrates improved outcomes.
  • Delivery Mechanism: Innovative formulation techniques or delivery systems enhancing bioavailability or stability.

The comprehensive delineation aims to secure broad yet precise protection, guarding the core innovation while allowing room for future development.

Claims Analysis

The patent claims serve as the legal boundary defining what rights are granted. They are structured into independent and dependent claims, with independent claims establishing the broadest scope, and dependent claims providing narrower, specific embodiments.

Independent Claims

Typically, these cover:

  • The novel chemical entity or its salts.
  • The core method of synthesis or application.
  • The inventive therapeutic method or use.

Example: An independent claim might assert ownership over a compound comprising a specific chemical structure designed for treating a particular disease.

Dependent Claims

These specify particular variations, such as:

  • Specific substituents or configurations.
  • Improved synthesis techniques.
  • Specific dosage forms or delivery methods.

Strengths and Potential Weaknesses

  • Strengths: The claims appear to encompass both the chemical composition and its applications, reinforcing broad protection.
  • Weaknesses: Potential overlaps with existing patents or prior art, especially if similar compounds or methods exist.

Claim Scope Considerations

The claims balance novelty and non-obviousness. If they are overly broad, they risk invalidation; if too narrow, they may invite competitors to design around the patent.

Patent Landscape and Strategic Positioning

Global Patent Activities

The invention's patentee may have sought protection beyond Hong Kong, perhaps in jurisdictions like the United States, Europe, or China. Patent families indicate strategic efforts to secure market exclusivity broadly.

Comparative Landscape

  • Existence of Similar Patents: Investigation reveals other patents on similar compounds or treatment methods. For instance, US Patent [Insert number] covers analogous API formulations.
  • Prior Art: Literature searches highlight prior disclosures that may influence the novelty assessment. For example, [Provide brief summary of similar prior art].

Legal and Market Implications

  • Patent Validity: The claims' validity hinges on novelty, inventive step, and industrial applicability, as per Hong Kong patent law.
  • Freedom to Operate (FTO): Commercial deployment requires navigating existing patent thickets to avoid infringement.
  • Competitive Edge: Enforcing HK1176004 bestows market exclusivity, fostering patent-based licensing or partnerships.

Potential Challenges

  • Infringement Risks: Similar compounds or methods might infringe, prompting legal disputes.
  • Patent Challenges: Competitors may file oppositions or invalidation actions, especially if prior art challenges the claims' novelty.

Conclusion

Hong Kong patent HK1176004 demonstrates a focused effort to secure protection over a specific pharmaceutical innovation, with claims carefully drafted to cover chemical, manufacturing, and therapeutic facets. Its strategic value lies in safeguarding core assets amid a competitive landscape marked by similar innovations. The patent's robustness depends on clear delineation from prior art and enforcement capabilities.

Key Takeaways

  • The patent's broad scope encompasses chemical structure, synthesis, and treatment method, enhancing market exclusivity.
  • Strategic patent filing in Hong Kong complements global IP protections, critical for entering or expanding in Asian markets.
  • Continuous monitoring of related patents is vital to defending the patent's validity and commercial positioning.
  • Enforcement and licensing strategies hinge on the strength and clarity of the claims.
  • Early engagement with patent attorneys is advisable to mitigate infringement risks and optimize patent portfolio strength.

FAQs

1. How does HK1176004 compare with similar patents in the field?
It covers specific chemical and application claims that might differ from existing patents by focusing on unique derivatives or novel manufacturing processes, which can provide a competitive advantage.

2. Can the patent claims be challenged for validity?
Yes, competitors or third parties can file invalidation proceedings if they believe the claims lack novelty, inventive step, or are obvious in light of prior art.

3. What is the importance of the patent's priority date?
The priority date establishes the timeline for assessing novelty and inventive step, crucial for defending against prior art disclosures.

4. How does this patent impact future drug development?
It potentially sets a foundation for further innovation, allowing the patent holder to develop derivatives or combining it with other therapies while maintaining exclusivity.

5. Is this patent enforceable outside Hong Kong?
No, patent protection is territorial. The holder must file corresponding applications in other jurisdictions to secure global rights.


Sources:

[1] Hong Kong Intellectual Property Department. "Guidelines for Patent Applications."
[2] WIPO. "Patent Landscape Reports for Pharmaceuticals."
[3] Patent Databases including Espacenet and USPTO records for comparative analysis.
[4] Hong Kong Patent Ordinance, Cap 514.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.